论文部分内容阅读
目的运用Meta分析方法综合评价中国耐多药肺结核患者治疗结局情况,并分析其在不同研究年份、不同样本量、不同患者类型之间的治疗结局差异。方法检索中国生物医学数据库(CBM)、中国期刊全文数据库(CNKI)、万方数据库、中文科技期刊数据库(VIP)、PubMed、Embase,收集建库至2015年关于中国耐多药肺结核患者治疗结局的数据,主要结局指标为治疗成功率,即在一定期间内某辖区中治愈和完成治疗的耐多药肺结核患者数占纳入治疗的耐多药肺结核患者总数的百分比。应用Stata l2.0软件进行单个样本率的Meta分析,并对年龄、性别、发表时间等因素进行亚组分析,并用漏斗图和Begg’s法检验发表偏倚。结果共纳入相关研究11项,总样本量为2 086人,异质性较小(I2=27.7,P>0.05),采用固定效应模型进行率的合并,中国耐多药肺结核患者治疗完成率为57%(95%CI:55%~59%),死亡率为7%(95%CI:4%~9%),失败率为25%(95%CI:18%~32%),丢失率为4%(95%CI:2%~6%),其他为0%(95%CI:0%~1%)。治疗成功率在不同研究年份、不同样本量、不同新发患者比例、不同女性患者比例、不同平均年龄亚组之间无统计学差异。结论我国耐多药肺结核患者治疗成功率有待进一步提高,耐多药患者的治疗结局研究开展时间较晚、研究较少、区域较集中,扩大范围并进行规范研究势在必行。
OBJECTIVE: To evaluate the treatment outcomes of MDR-TB patients in China by Meta-analysis and to analyze the treatment outcome differences among different years of study, different sample sizes and different patient types. Methods CBM, CNKI, VIP, PubMed and Embase were collected from China to collect information on the treatment outcome of MDR-TB patients in China. Data, with the primary outcome measure as the success rate of treatment, is the percentage of MDR-TB patients treated and treated in a jurisdiction over a period of time, as the percentage of MDR-TB patients treated and completed. Stata l2.0 software was used to carry out a single sample rate of meta-analysis, and sub-group analysis of age, gender, time of publication and other factors, and funnel charts and Begg’s test publication bias. Results A total of 11 studies were included in the study, with a total sample size of 2 086, with a small heterogeneity (I2 = 27.7, P> 0.05). The rate of consolidation was determined by using the fixed effect model. The treatment completion rate of MDR- The mortality rate was 7% (95% CI: 4% -9%) with a failure rate of 25% (95% CI: 18% -32% 4% (95% CI: 2% -6%) and 0% (95% CI: 0% -1%). The success rate of treatment in different years of study, different sample sizes, the proportion of different new patients, different female patients, different mean age subgroups between the no significant difference. Conclusion The success rate of MDR-TB treatment needs to be further improved in our country. The treatment outcome of MDR patients is relatively late, less studied, more concentrated in the area, and it is imperative to expand the scope and carry out standardized research.